Houston biotech firms resume trading after weeks-long suspensions

Securities trading for two Houston-based biotechnology firms have resumed after regulators questioned recent claims regarding potential Covid-19 treatments.

Both Moleculin Biotech Inc. (Nasdaq: MBRX) and CNS Pharmaceuticals Inc. (Nasdaq: CNSP) resumed trading on the Nasdaq on May 28. Trading for both firms had been halted since May 1. After closing at $2.76 per share on May 1, shares of CNSP were trading at $2.41 per share, down around 12.7%, when markets closed May 28, according to Yahoo Finance.…